Virax Biolabs Group has announced a purchase order with Cosmos Health for the launch and marketing of its Covid-19 and Influenza A+B Antigen Combo Rapid detection kits.
According to an earlier distribution agreement signed last September, Cosmos will exclusively distribute the kits in Greece and Cyprus.
The company also has an option for the distribution of ViraxClear branded test kits across Europe on a non-exclusive basis.
Cosmos CEO Greg Siokas said: “Covid-19 continues to threaten lives across the world. According to the World Health Organisation (WHO), as of 2 February 2023, there have been approximately 750 million confirmed covid-19 cases and about seven million covid-19-attributable deaths.”
“While the threat of influenza has been overshadowed by covid-19, the healthcare burden of influenza should not be overlooked.”
The single-use Covid-19 and Influenza A+B Antigen Combo Rapid test kit has been developed to use nasal swab specimens to qualitatively detect the nucleocapsid protein of influenza A and B viral antigens as well as covid-19 antigens.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Virax board of directors chairman and CEO James Foster said: “Covid-19, influenza A and influenza B are major sources of illness and mortality in humans across the globe.
“We are pleased to offer a dual solution, that can accurately identify infections related to these viruses, with results typically available in 15 minutes, and improve health outcomes through early identification.”
Established in 2013, Virax Biolabs is also engaged in the development of a T-Cell Test technology that would provide an immunology profiling platform to evaluate each individual’s immune risk profile against key global viral threats.